MCID: TCL005
MIFTS: 53

T-Cell Prolymphocytic Leukemia

Categories: Cancer diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

MalaCards integrated aliases for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 55 28 69
T-Cell Chronic Lymphocytic Leukemia 55
Lymphocytic Leukemia T-Cell Chronic 51
Leukemia, T-Cell, Chronic 69
T-Pll 55

Characteristics:

Orphanet epidemiological data:

55
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 55 ORPHA86871
MESH via Orphanet 42 D015461
UMLS via Orphanet 70 C2363142 C0023494
ICD10 via Orphanet 33 C91.6
ICD10 32 C91.6

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to prolymphocytic leukemia and b-cell lymphomas. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and IL-2 Pathway. The drugs Mitoxantrone and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 prolymphocytic leukemia 32.8 ATM MTCP1 MYC TCL1A
2 b-cell lymphomas 29.9 CDKN1B MS4A1 MYC TCL1A
3 leukemia, chronic lymphocytic 29.8 ATM CD52 MS4A1 TCL1A
4 leukemia 11.0
5 lymphoma 10.4
6 lactocele 10.3 JAK1 JAK3
7 jak3-deficient severe combined immunodeficiency 10.1 JAK1 JAK3
8 autoimmune lymphoproliferative syndrome, type v 10.1
9 t-cell leukemia 10.1
10 leukemia, chronic lymphocytic 2 10.1
11 diffuse large b-cell lymphoma 10.1
12 kaposi sarcoma 10.1
13 large granular lymphocyte leukemia 10.1
14 leukemia, b-cell, chronic 10.1
15 t-cell large granular lymphocyte leukemia 10.1
16 t-cell lymphoma 1a 10.1
17 ataxia-telangiectasia 10.1
18 ataxia and polyneuropathy, adult-onset 10.1
19 sarcoma 10.1
20 large cell carcinoma with rhabdoid phenotype 10.1 SMARCB1 VEGFA
21 polycythemia vera 10.0 ABL1 JAK1 JAK3
22 pityriasis lichenoides 9.9 CD7 MS4A1
23 retinitis 9.9
24 hydrops, lactic acidosis, and sideroblastic anemia 9.9
25 acute liver failure 9.9
26 thyroiditis 9.9
27 vasculitis 9.9
28 blood group, i system 9.9
29 chromosome 8q duplication 9.9
30 peripheral t-cell lymphoma 9.9
31 prostate cancer 9.9
32 endotheliitis 9.9
33 nijmegen breakage syndrome 9.9
34 mycobacterium tuberculosis 1 9.9
35 panuveitis 9.9
36 myocardial infarction 9.9
37 scleritis 9.9
38 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
39 anterior scleritis 9.9
40 gastric cancer 9.9
41 prostatitis 9.9
42 infantile liver failure syndrome 1 9.9
43 purpura 9.9
44 mantle cell lymphoma 9.9 ATM CDKN1B MYC
45 b cell prolymphocytic leukemia 9.9 MS4A1 MYC
46 nervous system cancer 9.9 CDKN1B MYC SMARCB1
47 oral squamous cell carcinoma 9.8 CDKN1B MYC VEGFA
48 primary effusion lymphoma 9.7 CDKN1B MYC TCL1A VEGFA
49 precursor t-cell acute lymphoblastic leukemia 9.5 ABL1 CD7 MYC TCL1A
50 lymphoma, non-hodgkin, familial 9.3 ATM CD52 CDKN1B MS4A1 MYC TCL1A

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.3 ABL1 MYC SMARCB1
2 Decreased viability GR00221-A-2 10.3 ABL1 CHEK2 SMARCB1
3 Decreased viability GR00221-A-3 10.3 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
4 Decreased viability GR00221-A-4 10.3 ATM CHEK2
5 Decreased viability GR00342-S-1 10.3 ABL1
6 Decreased viability GR00342-S-2 10.3 ABL1 CHEK2
7 Decreased viability GR00342-S-3 10.3 ABL1
8 Decreased viability GR00381-A-1 10.3 SMARCB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 ABL1 SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.3 ATM ABL1 JAK3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.3 ATM SMARCB1 JAK3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.3 ATM CHEK2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.3 CHEK2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.3 ATM SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.3 ABL1 CHEK2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.3 ATM JAK3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.3 ABL1 ATM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.3 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.3 ATM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.3 ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.3 SMARCB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.3 SMARCB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.3 CHEK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.3 ATM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.3 ATM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.3 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.3 ABL1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.3 ATM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 ABL1 JAK3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.3 JAK3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.3 ATM
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 ATM
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.3 ABL1 SMARCB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.3 ATM ABL1 CHEK2 JAK3 SMARCB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.3 JAK3
37 Decreased viability in esophageal squamous lineage GR00235-A 9.91 ABL1 CD52 CD7 CDKN1B CHEK2 JAK1
38 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.77 ATM CHEK2 JAK1 JAK3 ABL1
39 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.58 ATM CDKN1B JAK1
40 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK1 JAK3
41 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 ABL1 ATM BRCC3 CDKN1B CHEK2 NFKB1

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
2 endocrine/exocrine gland MP:0005379 10.02 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
3 immune system MP:0005387 9.93 MYC NFKB1 SMARCB1 VEGFA ABL1 ATM
4 digestive/alimentary MP:0005381 9.91 ABL1 CDKN1B JAK3 MYC NFKB1 SMARCB1
5 liver/biliary system MP:0005370 9.5 ABL1 CDKN1B JAK1 MYC NFKB1 SMARCB1
6 neoplasm MP:0002006 9.1 ATM CDKN1B CHEK2 MYC SMARCB1 VEGFA

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
2
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
5
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
7
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
8
alemtuzumab Approved, Investigational Phase 2 216503-57-0
9
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
10
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
11
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
12
Melphalan Approved Phase 2,Phase 1 148-82-3 460612 4053
13
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
14
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
15
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
16
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
17
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
18
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
19 Analgesics Phase 2
20 Alkylating Agents Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 2,Phase 1
22 Cyclosporins Phase 2,Phase 1
23 Vidarabine Phosphate Phase 2,Phase 1
24 Dermatologic Agents Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 2
26 Anti-Bacterial Agents Phase 2,Phase 1
27 Anti-Infective Agents Phase 2,Phase 1
28 Antifungal Agents Phase 2,Phase 1
29 Immunosuppressive Agents Phase 2,Phase 1
30 Antimetabolites Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 2,Phase 1
33 Antirheumatic Agents Phase 2,Phase 1
34 Calcineurin Inhibitors Phase 2,Phase 1
35 Antitubercular Agents Phase 2,Phase 1
36 Antiviral Agents Phase 2,Phase 1
37 Podophyllotoxin Phase 2,Phase 1 518-28-5
38 Nitrogen Mustard Compounds Phase 2,Phase 1
39 Etoposide phosphate Phase 2,Phase 1
40 Keratolytic Agents Phase 2,Phase 1
41 Antimitotic Agents Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
43 alanine Nutraceutical Phase 2,Phase 1
44 phenylalanine Nutraceutical Phase 2,Phase 1
45
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
46
Busulfan Approved, Investigational Phase 1 55-98-1 2478
47
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
48 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
49 Antilymphocyte Serum Phase 1
50 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 14)

# Name Status NCT ID Phase Drugs
1 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
2 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
3 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
4 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
6 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Active, not recruiting NCT00005803 Phase 1, Phase 2 Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
7 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia Terminated NCT00413478 Phase 2 5-Azacytidine
8 Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Withdrawn NCT01162031 Phase 2 Velcade
9 A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) Completed NCT00749502 Phase 1 MK-4827
10 Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) Completed NCT00124189 Phase 1 GRN163L
11 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Recruiting NCT02512497 Phase 1 Romidepsin;Busulfan;Fludarabine;Thymoglobulin
12 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Active, not recruiting NCT01094860 Phase 1 Nelarabine
13 Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
14 Registry of the German CLL Study Group Recruiting NCT02863692

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 28

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

38
T Cells, Bone Marrow, Bone, Liver, Skin, Spleen, Lymph Node

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 147)
# Title Authors Year
1
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
2
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
3
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
4
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
5
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
6
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
7
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
8
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
9
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
10
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
11
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
12
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
13
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
14
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
15
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
16
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
17
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
18
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
19
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
20
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
21
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
22
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
23
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
24
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
25
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
26
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
27
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
28
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
29
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
30
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
31
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014
32
Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. ( 25068103 )
2014
33
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. ( 24825865 )
2014
34
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
35
T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: Metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities. ( 25238936 )
2014
36
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
37
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. ( 24446122 )
2014
38
Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. ( 24977988 )
2014
39
T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry. ( 21987484 )
2013
40
[Splenic rupture associated with aggressive conversion of indolent T-cell prolymphocytic leukemia]. ( 23676644 )
2013
41
Immunophenotypic characterization of T-cell prolymphocytic leukemia. ( 24124154 )
2013
42
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. ( 24048415 )
2013
43
T-cell prolymphocytic leukemia. ( 23382603 )
2013
44
Coronary vasculitis associated with T-cell prolymphocytic leukemia. ( 23731632 )
2013
45
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. ( 23512246 )
2013
46
Cutaneous presentation of T-cell prolymphocytic leukemia. ( 23513557 )
2013
47
Cerebriform variant type of T cell prolymphocytic leukemia with complex karyotype including an additional segment at 1p36.1. ( 23054642 )
2012
48
Erythematous eruption with marked conjunctival injection--quiz case. Diagnosis: leukemia cutis with conjunctival involvement in the setting of T-cell prolymphocytic leukemia (T-PLL). ( 23069962 )
2012
49
"T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach". ( 23211026 )
2012
50
A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia. ( 22517037 )
2012

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh37 Chromosome 11, 108199929: 108199929
2 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh37 Chromosome 11, 108170479: 108170479
3 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh37 Chromosome 11, 108172506: 108172506

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
7 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
8 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
9 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
10 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
11 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
12 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
13 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
14 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
15 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
16 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
17 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
18 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
19 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
20 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
21 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
22 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
23 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
24 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
25 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
26 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
27 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
28 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
29 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
30 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
31 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
32 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
33 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
34 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
35 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
36 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
37 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
38 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
39 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
40 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
41 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
42 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
43 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
44 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
2
Show member pathways
13.18 ABL1 CDKN1B JAK1 JAK3 MYC NFKB1
3
Show member pathways
13.02 ATM CDKN1B JAK1 JAK3 MYC NFKB1
4
Show member pathways
12.89 ATM CHEK2 JAK1 JAK3 NFKB1
5 12.78 ABL1 CDKN1B JAK1 JAK3 MYC NFKB1
6
Show member pathways
12.76 CDKN1B JAK1 JAK3 MYC NFKB1
7
Show member pathways
12.63 ATM CDKN1B JAK1 JAK3 MTCP1 MYC
8
Show member pathways
12.56 JAK1 JAK3 MYC NFKB1
9
Show member pathways
12.56 CDKN1B JAK1 MYC NFKB1 VEGFA
10 12.49 ATM BRCC3 CDKN1B CHEK2
11 12.48 ABL1 ATM CDKN1B MYC NFKB1 VEGFA
12
Show member pathways
12.4 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
13
Show member pathways
12.39 JAK1 JAK3 NFKB1 VEGFA
14
Show member pathways
12.39 CDKN1B JAK1 JAK3 MYC NFKB1
15
Show member pathways
12.35 ABL1 ATM BRCC3 CHEK2
16
Show member pathways
12.34 ABL1 ATM CDKN1B CHEK2 MYC
17 12.33 ABL1 ATM CDKN1B CHEK2 MYC
18 12.29 ATM CHEK2 JAK1 JAK3 MYC NFKB1
19 12.28 CDKN1B JAK1 JAK3 NFKB1
20 12.27 CDKN1B JAK1 JAK3 MYC NFKB1
21
Show member pathways
12.26 CDKN1B JAK1 JAK3 NFKB1 VEGFA
22 12.24 ATM CDKN1B MYC NFKB1
23
Show member pathways
12.21 CDKN1B CHEK2 MYC NFKB1
24 12.18 JAK1 MYC NFKB1 VEGFA
25 12.16 ATM CHEK2 MYC NFKB1
26 11.98 JAK1 JAK3 MYC VEGFA
27
Show member pathways
11.96 JAK1 JAK3 MYC NFKB1
28
Show member pathways
11.92 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
29 11.89 CDKN1B NFKB1 VEGFA
30 11.88 CDKN1B NFKB1 VEGFA
31
Show member pathways
11.85 JAK1 JAK3 NFKB1
32 11.85 CDKN1B MYC NFKB1
33 11.83 ABL1 CDKN1B MYC
34 11.83 ABL1 ATM CDKN1B MYC NFKB1
35
Show member pathways
11.82 ABL1 ATM CHEK2
36
Show member pathways
11.8 ATM CHEK2 SMARCB1
37 11.73 ATM CDKN1B MYC
38 11.7 CDKN1B JAK1 MYC
39 11.68 ATM CHEK2 MYC
40
Show member pathways
11.68 JAK1 JAK3 MYC NFKB1
41 11.62 ABL1 ATM CHEK2
42
Show member pathways
11.62 CDKN1B JAK1 MYC NFKB1
43 11.6 ABL1 CDKN1B SMARCB1
45 11.56 JAK1 MYC NFKB1 VEGFA
46 11.54 ABL1 ATM CDKN1B MYC
47 11.54 ABL1 ATM CDKN1B MYC NFKB1
48 11.49 ATM CHEK2 NFKB1
49 11.48 CDKN1B MYC NFKB1 VEGFA
50
Show member pathways
11.45 JAK1 JAK3 VEGFA

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.13 ABL1 JAK1 JAK3
2 protein complex GO:0043234 9.1 ABL1 CDKN1B MTCP1 MYC SMARCB1 TCL1A

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 CDKN1B MYC NFKB1 TCL1A VEGFA
2 cellular response to DNA damage stimulus GO:0006974 9.89 ABL1 ATM BRCC3 CHEK2 MYC
3 phosphorylation GO:0016310 9.88 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
4 protein autophosphorylation GO:0046777 9.76 ABL1 ATM CHEK2 JAK1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 MTCP1 TCL1A VEGFA
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.65 ATM CDKN1B CHEK2
7 DNA repair GO:0006281 9.65 ABL1 ATM BRCC3 CHEK2 SMARCB1
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.61 ABL1 ATM CHEK2
9 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.59 ABL1 VEGFA
10 replicative senescence GO:0090399 9.58 ATM CHEK2
11 interleukin-15-mediated signaling pathway GO:0035723 9.58 JAK1 JAK3
12 cellular response to angiotensin GO:1904385 9.57 MYC NFKB1
13 positive regulation of response to DNA damage stimulus GO:2001022 9.56 ATM MYC
14 signal transduction in response to DNA damage GO:0042770 9.52 ABL1 CHEK2
15 positive regulation of mitochondrial membrane potential GO:0010918 9.51 MYC TCL1A
16 peptidyl-tyrosine autophosphorylation GO:0038083 9.5 ABL1 JAK1 JAK3
17 interleukin-9-mediated signaling pathway GO:0038113 9.37 JAK1 JAK3
18 ovarian follicle development GO:0001541 9.33 ATM MYC VEGFA
19 cell cycle arrest GO:0007050 9.26 ABL1 ATM CDKN1B MYC
20 DNA damage induced protein phosphorylation GO:0006975 8.8 ABL1 ATM CHEK2
21 cell cycle GO:0007049 10 ATM BRCC3 CDKN1B CHEK2 SMARCB1
22 protein phosphorylation GO:0006468 10 ABL1 ATM CHEK2 JAK1 JAK3

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 ABL1 ATM CHEK2 JAK1 JAK3
2 protein phosphatase binding GO:0019903 9.33 CDKN1B JAK1 JAK3
3 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.13 ABL1 JAK1 JAK3
4 kinase activity GO:0016301 9.1 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....